Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amvuttra
Pharma
Alnylam's Amvuttra off to promising start in ATTR-CM
After BridgeBio blew away analyst projections for its new ATTR-CM drug Attruby, Alnylam countered with positive news for its Amvuttra.
Kevin Dunleavy
May 1, 2025 11:46am
Alnylam's Amvuttra wins key cardiomyopathy FDA nod
Mar 20, 2025 7:40pm
Market growth will help spark sales of Amvuttra, Alnylam says
Feb 13, 2025 2:08pm
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
Pfizer's ATTR drug needs hefty discount, says ICER draft report
Jul 18, 2024 4:37pm
Alnylam touts 'big-win scenario' for closely watched heart trial
Jun 24, 2024 10:53am
